Vesugen (KED) is studied in vitro as a vascular / endothelium-directed short-peptide probe. In organotypic and dissociated cell cultures it has been reported to stimulate the proliferation marker Ki-67 and to reduce apoptosis (decreased p53), used experimentally to study endothelial cell proliferation and vascular-tissue gene-expression programmes.
It is a tool for probing chromatin-level transcriptional regulation in vascular and neuroimmunoendocrine cell systems. Observed effects depend on concentration, model system and exposure conditions.
Applications in Research
- In-vitro endothelial / vascular cell proliferation and apoptosis-marker studies
- Neuroimmunoendocrine organotypic-culture gene-expression research
- Reference probe for short-peptide transcriptional regulation
Specifications Summary
| Parameter |
Typical Value / Range |
| Purity (HPLC) |
≥ 99% |
| Appearance |
White to off-white lyophilised powder |
| Molecular Weight |
390.39 g/mol |
| Peptide Type |
Synthetic tripeptide |
| Solubility |
Water, buffered aqueous solutions |
| Storage |
–20 °C, desiccated, dark |
| Pack Size |
20 mg (total) |
Precautions & Notes
- Experimental behaviour is dependent on concentration, model system and exposure conditions
- Appropriate experimental controls are recommended
- Prolonged exposure to light, elevated temperature or aqueous environments may reduce stability
- Intended strictly for laboratory research use; not for human or veterinary application
References
Chalisova NI, Lopatina NG, Khavinson VKh, et al. Effect of tripeptide Lys-Glu-Asp on physiological activity of neuroimmunoendocrine system cells. Bull Exp Biol Med. 2012;153(4):569-572.
https://link.springer.com/article/10.1007/s10517-012-1768-7
Khavinson VKh, Popovich IG, et al. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053.
https://www.mdpi.com/1420-3049/26/22/7053
PubChem Compound Summary, CID 87571363 (Lys-Glu-Asp).
https://pubchem.ncbi.nlm.nih.gov/compound/87571363
Keywords: Vesugen, KED, synthetic tripeptide
